InvestorsHub Logo
Followers 30
Posts 2489
Boards Moderated 0
Alias Born 05/03/2012

Re: couldbebetter post# 367721

Thursday, 01/27/2022 9:26:46 AM

Thursday, January 27, 2022 9:26:46 AM

Post# of 430192
Denner might be looking to gain control to stop them from acquiring another pharma to add to the pipeline, would be really stupid if Amarin. More dilution or cash burn through when they have a pipeline in a pill. I swear I think the entire executive team has ADD. Focus on your product, sales while adding more diseases to V. Why not seek the addition of evaporate to the label and what about any others they found from reduce it. The more they add the longer they can protect V in Europe before the patent fight. Next, why are they so slow with other market deals? File for approval now in markets you want to keep and partner the others. This brings in cash and adds to the valuation.
The combo pill is a blockbuster and insurance will cover if they target a total cost current V plus generic statin. The generics charge insurance companies hundreds for a script and I bet it costs dollars to make.
Then, long term transition is one a day V, or even a trial at higher concentrations.
They have plenty in house to drive value and just need someone to kick or drag them there.
COVID is a bit of a hurdle but that should not stop drug development, regulatory activity and partnerships.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News